5DT Stock Overview
A clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Entera Bio Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.47 |
| 52 Week High | US$3.12 |
| 52 Week Low | US$0.48 |
| Beta | 1.59 |
| 11 Month Change | -10.91% |
| 3 Month Change | -5.77% |
| 1 Year Change | 133.33% |
| 33 Year Change | -51.64% |
| 5 Year Change | n/a |
| Change since IPO | -67.48% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5DT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.5% | -0.2% | 0.8% |
| 1Y | 133.3% | -16.9% | 9.1% |
Return vs Industry: 5DT exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 5DT exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 5DT volatility | |
|---|---|
| 5DT Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5DT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5DT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 19 | Miranda Toledano | www.enterabio.com |
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The company leverage its N-Tab, an oral delivery technology, which is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. Its advanced product candidate is EB613 (oral PTH (1-34)) that is entering into Phase 3 development as the first oral, osteoanabolic (bone-building) once-daily tablet treatment for post-menopausal women with low bone mineral density and high-risk osteoporosis.
Entera Bio Ltd. Fundamentals Summary
| 5DT fundamental statistics | |
|---|---|
| Market cap | €55.80m |
| Earnings (TTM) | -€8.74m |
| Revenue (TTM) | €94.33k |
621.3x
P/S Ratio-6.7x
P/E RatioIs 5DT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5DT income statement (TTM) | |
|---|---|
| Revenue | US$99.00k |
| Cost of Revenue | US$90.00k |
| Gross Profit | US$9.00k |
| Other Expenses | US$9.19m |
| Earnings | -US$9.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 9.09% |
| Net Profit Margin | -9,270.71% |
| Debt/Equity Ratio | 0% |
How did 5DT perform over the long term?
See historical performance and comparison